News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ) Pulls File to Extend Velcade's Use in EU


7/5/2012 7:35:03 AM

The European Medicines Agency has been formally notified by US health care giant Johnson & Johnson’s (NYSE: JNJ) European subsidiary Janssen-Cilag International of its decision to withdraw its application for an extension of the therapeutic indication for the centrally authorized drug Velcade (bortezomib). On September 2, 2011, Janssen-Cilag submitted an application to extend the marketing authorization for Velcade in combination with rituximab for the treatment of patients with relapsed follicular non-Hodgkin's lymphoma. At the time of the withdrawal the application was under review by the EMA’s Committee for Medicinal Products for Human Use (CHMP).



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES